Tag Archives: #JPM19

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry. For context, by JPM I don’t mean the actual J.P. Morgan Healthcare Conference at the Westin

2018 was a incredible boom year in the number of new biotech offerings, with 60 IPOs on US exchanges. But as we’re all painfully aware, after the overall biotech market ($XBI) touched its all-time high in August, the last third